(888)281-6222
Our clients range from leading multinational companies to small startups among 5 different countries.
With our products and services, our clients have successfully accomplished many projects in CAR T-Cell therapy field.
We have established robust supply chain.
We provide accurate and convenient detection products and technical solutions for CAR T-Cell development, quality control and clinical monitoring.
Our product have the highest sensitivity for CAR T-Cell detection in the market.
More accurate! more precise! more sensitive!
Application of R19M, An FMC63 scFv Idiotype Monoclonal Antibody Anti-CD19 CAR-T cell therapy With the development of cancer immunotherapy, Chimeric AntigenReceptor (CAR)-T cell, which combines
Two CD19-specific CARs approved by US FDA in 2017 have induced prominent responses in patients with refractory leukemia and lymphomas. However, Grade 3/4 CRS and
Immune checkpoint inhibitor was undoubtedly a breakthrough in cancer therapy. Since FDA approved Pembrolizumab and Nivolumab for melanoma in 2014, PD-1/PD-L1 blockade has been proven
Our product have the highest sensitivity for CAR T-Cell detection in the market.